← Back to Screener
REGENXBIO Inc. (RGNX)
Price$7.14
Value ScoreC
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-51.44%
Price vs S&P 500 (4W)-28.11%
VGM Score36.85
Market Capitalization$362.40M
All Metrics
Book Value / Share (Quarterly)$0.41
P/TBV (Annual)1.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.78%
Cash Flow / Share (Quarterly)$-4.58
Price vs S&P 500 (YTD)-62.25%
Gross Margin (TTM)68.19%
Net Profit Margin (TTM)-330.23%
EPS (TTM)$-5.59
10-Day Avg Trading Volume2.11M
EPS Excl Extra (TTM)$-5.59
Revenue Growth (5Y)1.97%
EPS (Annual)$-3.76
ROI (Annual)-66.91%
Gross Margin (Annual)88.09%
Net Profit Margin (5Y Avg)-179.96%
Cash / Share (Quarterly)$2.92
Revenue Growth QoQ (YoY)-92.82%
ROA (Last FY)-42.80%
Revenue Growth TTM (YoY)-43.96%
EBITD / Share (TTM)$-4.65
ROE (5Y Avg)-79.66%
Operating Margin (TTM)-292.28%
Cash Flow / Share (Annual)$-2.48
P/B Ratio17.19x
P/B Ratio (Quarterly)20.52x
Net Income / Employee (Annual)$-522,600
EV / Revenue (TTM)5.97x
Net Interest Coverage (TTM)-4.91x
ROA (TTM)-61.02%
EV / EBITDA (TTM)4.37x
EPS Incl Extra (Annual)$-3.76
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)2.46x
3-Month Avg Trading Volume1.17M
52-Week Price Return-21.85%
Revenue / Employee (TTM)$236,700
Tangible BV / Share (Quarterly)$8.25
P/S Ratio (Annual)2.13x
Asset Turnover (Annual)0.38x
52-Week High$16.19
Operating Margin (5Y Avg)-174.20%
EPS Excl Extra (Annual)$-3.76
CapEx CAGR (5Y)-38.26%
Tangible BV CAGR (5Y)23.04%
26-Week Price Return-35.51%
Quick Ratio (Annual)2.28x
13-Week Price Return-19.89%
Total Debt / Equity (Annual)1.82x
Current Ratio (Quarterly)2.62x
Enterprise Value$524.50M
Revenue / Share Growth (5Y)-4.43%
Asset Turnover (TTM)0.18x
Book Value / Share Growth (5Y)-27.50%
Revenue / Employee (Annual)$459,400
Pretax Margin (Annual)-113.75%
Cash / Share (Annual)$4.52
3-Month Return Std Dev108.23%
Gross Margin (5Y Avg)69.44%
Net Income / Employee (TTM)$-781,700
ROE (Last FY)-188.72%
Net Interest Coverage (Annual)-7.70x
EPS Basic Excl Extra (Annual)$-3.76
P/FCF (TTM)11.11x
Receivables Turnover (TTM)6.22x
Total Debt / Equity (Quarterly)8.41x
EPS Incl Extra (TTM)$-5.59
Receivables Turnover (Annual)7.28x
ROI (TTM)-92.88%
P/S Ratio (TTM)4.13x
Pretax Margin (5Y Avg)-179.44%
Revenue / Share (Annual)$3.30
Tangible BV / Share (Annual)$11.92
Price vs S&P 500 (52W)-50.06%
Year-to-Date Return-51.32%
5-Day Price Return10.39%
EPS Normalized (Annual)$-3.76
ROA (5Y Avg)-31.92%
Net Profit Margin (Annual)-113.75%
Month-to-Date Return-21.85%
Cash Flow / Share (TTM)$-5.59
EBITD / Share (Annual)$-2.82
Operating Margin (Annual)-94.58%
LT Debt / Equity (Annual)1.43x
ROI (5Y Avg)-48.11%
LT Debt / Equity (Quarterly)7.74x
EPS Basic Excl Extra (TTM)$-5.59
P/TBV (Quarterly)2.36x
P/B Ratio (Annual)7.10x
Pretax Margin (TTM)-330.23%
Book Value / Share (Annual)$2.02
Price vs S&P 500 (13W)-29.63%
Beta1.01x
P/FCF (Annual)2.69x
Revenue / Share (TTM)$1.68
ROE (TTM)-232.50%
52-Week Low$5.46
vGradeC
gGradeF
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.72est. -1.37
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RGNXREGENXBIO Inc. | C | F | D | $7.14 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Regenxbio is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform based on adeno-associated virus (AAV) vectors. The company targets retinal, neuromuscular, and neurodegenerative diseases by delivering genes to cells to correct genetic defects or enable therapeutic protein production. Its pipeline addresses unmet medical needs in genetic and degenerative disorders.